GSK breaks cloud cover with financial results

Share this article:
Andrew Witty
Andrew Witty

While GlaxoSmithKline says it's too early to calculate the financial impact of China's investigation over bribery and corruption allegations, CEO Andrew Witty said during Wednesday's second-quarter earnings call that there will be a cost.

The British drug maker is under scrutiny over a series of allegations that have ensnared peers and is also being examined over sloppy clinical trial practices, as revealed by the New York Times Tuesday. Bernstein analyst Tim Anderson wrote in a research note, however, that the impact on sales in the country could be limited because “China only accounts for low single-digits percent of total company revenues.” The company noted earlier this week that recent negotiations will likely lead to lower drug prices for Chinese customers.

Despite that backdrop, GSK eked out a bit of positivity, saying it closed the second quarter with $6.6 billion in sales, a 2% increase over the same period last year. Vaccines, oncology and respiratory sales drove a 5% growth in US sales over the same period last year.

The sales volume of Advair (asthma) helped contribute to this mix, a short-term positive, in that the drug is nearing its off-patent status, and its next-generation replacement, the recently approved Breo-Ellipta, is not considered a significant improvement over the brand, and by association, the generics that are expected to enter the market.

Generic versions of antidepressant Paxil contributed to the 5% drop in Japan sales for the quarter, an overall slide that included a 43% falloff in vaccines sales and 3% fall in pharmaceutical sales.

Bernstein's Anderson added Wednesday that the company's year-to-date performance indicates GSK is off to an overall good start, partly due to the Breo/Ellipta approval. And its creation of an Established Products division, Anderson wrote, “shows the management team is trying creative ways to manage the business...similar to what Pfizer is doing.”

Anderson also noted that GSK's long-term outlook is “fairly robust,” because of a diverse portfolio, emerging markets presence and “lower future patent expirations than many peer companies.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...